Lymphatic Education
& Research Network

Other Grants & Awards Programs

• The Alfie Milne Young Investigator Award for Complex Lymphatic Anomalies

  The Alfie Milne Young Investigator Award is a one-year grant designed to support early career researchers, such as postdoctoral and clinical fellows or instructors, pursuing promising research ideas related to complex lymphatic anomalies including Gorham Stout Disease (GSD), Generalized Lymphatic Anomaly (GLA), Kaposiform Lymphangiomatosis (KLA) and Central Conducting Lymphatic Anomaly (CCLA). This grant aims to cultivate the best and brightest researchers of the future who demonstrate a commitment to a career in lymphatic research. This is a mentored award, and the research project is conducted under the guidance of a scientific mentor. Applications in all areas of lymphatic research are accepted from U.S. and international applicants.

  Alfie Milne Young Investigator Award is a one-year grant totaling $25,000 that supports personnel and/or direct research expenses. This award is made possible by a charitable donation from Lymphangiomatosis & Gorham’s Disease Alliance, United Kingdom (LGDA UK).

  Eligibility Criteria
  This RFA is open globally. International applicants are invited to apply. Applicants must have a PhD, MD, or MD/PhD or equivalent and must not have achieved an appointment higher than Instructor.

  How to Apply:
  Submit a LOI to the LMI. If your LOI is selected, you will be invited to submit a full grant application. Click the link below to download instructions and form templates for the Alfie Milne Young Investigator application.

  Letter of Interest Instructions:
  Letter of Interest (LOI) guidelines can be found at https://bit.ly/AlfieYI. The completed one-page LOI is to be emailed to grants@lmiresearch.org and due no later than Friday, May 19, 2023 by 11:59pm (EST).

  Full Applications are by invitation only.

  Proposal Due Date: Friday, July 28, 2022 no later than 11:59pm (EST)
  Submission guidelines can be found at https://bit.ly/AlfieYI.
  Completed applications are to be emailed to grants@lmiresearch.org.

  Grant Review Process:
  1) Grants will be reviewed for scientific content and relevance to the goals of the RFA.
  2) Full applications proceed through a two-step review process. The first step includes external review and rating with an assessment of the strengths and weaknesses of each application based on the defined review criteria described below. During the second step, funding recommendations are determined based on an assessment of the reviewer scores and written comments. Final decision of funding will be made by Leadership of LMI, LGDA and LGDA Europe.

  Anonymous reviewer feedback is shared with the applicant.

  Confidentiality:
  The LMI Programs are a confidential process and all content of the LOIs and Full Applications will be kept confidential. In order to encourage sharing of new techniques and findings to advance science, after funding decisions are made, the LMI will share a non-confidential lay summary of the research proposals received (required with your letter of intent), including those that were not funded, with LGDA and LGDA Europe (funding organizations). The LMI aims to respect and protect the integrity of your work, and thus will not release any proprietary information.

  Learn More >
• 2023 AVF-JOBST Clinical Research Grant

  The AVF 2023 AVF-JOBST Clinical Research Grant will provide a $85,000 grant over two years for original, clinical research in venous diseases, lymphatic diseases, or lipedema with an emphasis on:

  - Prevention of disease and its progression
  - Diagnosis of disease
  - The science of management of the above conditions, especially with compression therapy

  This opportunity is open to:

  - Residents and fellows in a training program located in the United States
  - Physicians who have completed their training within the past ten (10) years and are currently based in the United States
  - Applicants who have not previously received this award

  Either the applicant or their mentor must be an AVF Member at the time of submission. The awardee is expected to join the AVF and maintain their membership for the duration of the grant period.

  Submission deadline: Saturday, October 15, 2022

  For more information regarding eligibility and the application process or to submit an application, click here.

  Learn More >
• 2022 Million Dollar Bike Ride Pilot Grant Program

  The Orphan Disease Center (ODC) at the University of Pennsylvania is pleased to announce the 2022 Million Dollar Bike Ride Pilot Grant Program. The program is now open and offering up to 40 different research grant opportunities focusing on 30 different rare diseases. This program provides a one‐year grant to support research related to a rare disease represented in the 2022 Million Dollar Bike Ride. The number of awards and dollar amounts vary per disease based on fundraising totals by each disease team. This Request for Applications (RFA) is open to the international research community. All individuals holding a faculty‐level appointment at an academic institution or a senior scientific position at a non-profit institution or foundation are eligible to respond to this RFA.

  

  Letters of Interest (LOIs) are due no later than Friday, September 16, 2022 by 8pm EST.

  For more details about this grant program, rare disease focus areas, and how to apply, please visit the ODC Website.  To apply, click here.

  Learn More >
• Patient-Centered Outcomes Research Institute

  PCORI funds research into conditions that affect large numbers of people across a range of populations; conditions that place a heavy burden on individuals, families, specific populations, and society; and rare diseases, which are difficult to study. PCORI funds research through organizations and not individuals.
  

  PCORI funds research that offers patients and caregivers the information they need to make important healthcare decisions. Our scientific research portfolio is divided among two programs, which together reflect our National Priorities for Research. Each program leads the development of PCORI Funding Announcements that may be either broad calls for applications or targeted to specific topics. These programs also participate in the selection of awards and oversee the projects as they progress.

  In addition, the Evaluation and Analysis program provides evaluation expertise, while the Engagement program gives patients, caregivers, clinicians, and other healthcare stakeholders opportunities for meaningful involvement in all our activities.

  Learn More >
• DOD’s Congressionally Directed Medical Research Programs (CDMRP) - BCRP Pre-Announcements

  Last year researchers looking at the intersection of lymphedema and breast cancer were encouraged to compete for funding opportunities through the CDMRP’s Breast Cancer Research Program (BCRP). Please see the information below in this regard.

  The Fiscal Year 2019 (FY19) Defense Appropriation Act provides funding for the peer reviewed programs managed by the Department of Defense (DOD) office of Congressionally Directed Medical Research Programs (CDMRP). Recently released pre-announcements may be found at http://cdmrp.army.mil/pubs/press/press to allow investigators time to plan and develop ideas for submission to the anticipated FY19 funding opportunities.
  
  FY19 funding opportunities are anticipated to be released in January 2019 for the following programs:
  
  Breast Cancer Research Program
  Ovarian Cancer Research Program
  
  Descriptions of each of the anticipated funding opportunities, eligibility, key mechanism elements, and funding can be found in the respective Program pre-announcement.  FY19 pre-announcements can be found in the CDMRP home page features at http://cdmrp.army.mil.
  
  Researchers investigating the intersection of lymphedema and breast cancer may be interested in the following grant opportunities recently released.
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Innovator Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312196
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Breakthrough Fellowship Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312197
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Breakthrough Award Level 4 Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312198
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Era of Hope Scholar Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312195
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Distinguished Investigator Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312176

  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Breakthrough Award Levels 1 and 2
  Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312177

  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Breakthrough Award Level 3 Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312178

  Learn More >
• DOD’s Congressionally Directed Medical Research Programs (CDMRP) - PRMRP Grant Opportunities

  Peer Reviewed Medical Research Program (PRMRP) Grant Opportunities. – PRMRP funds medical research for a list of conditions and diseases that have been identified by Congress as disproportionately affecting military personnel. LE&RN will be working over the course of this year to include “lymphatic diseases” to this list.
  
  This year’s PRMRP includes “burn pit exposures” and “vascular malformations.” Any researchers looking at this connection between burn pit exposures and the onset of lymphedema should look at the opportunities below. Researchers who are working on research involving vascular or lymphatic malformations may also find funding through these opportunities. Researchers are also encouraged to apply for funding through the designation of vascular malformations as this may encompass vascular anomalies of only veins, only lymph vessels, both veins and lymph vessels, or both arteries and veins.
  (https://www.hopkinsmedicine.org/interventional-radiology/conditions/malformations/index.html)

  LE&RN is working to include “lymphatic diseases” as eligible for study through the fiscal year (FY) 2020 PRMRP and this will definitely improve the ability of researchers to compete successfully for this funding, but the categories above should be seen as an opportunity for researchers to get their foot in the PRMRP’s door.
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Investigator-Initiated Research Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312036
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Technology/Therapeutic Development Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312037
  

  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Discovery Award
  Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312033
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Clinical Trial Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312034
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Focused Program Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312035

  Learn More >
• 
  Lymphatic researchers needed for NIH Study Sections

  NIH has requested that LE&RN assemble and deliver to NIH a list of lymphatic researchers who are willing to serve on NIH Study Sections. They have identified the following three Study Sections that review lymphatic grant proposals:

  * Hypertension and Microcirculation (HM) Study Section reviews applications dealing with propulsion of lymph, lymphatic tone, and pathogenesis of lymphedema with more focus on functional studies; sometimes reviews applications about the lymphatic system in infection and inflammation depending on the outcome of research, namely whether focused on lymphatics or infection.
  
  
  * Immunity and Host Defense (IHD) and Innate Immunity and Inflammation (III) Study Sections may review applications that address lymphatic role in infection.
  
  
  * Cardiovascular Differentiation and Development (CDD) Study Section reviews applications involving lymphatic development, lymphangiogenesis, and lymphedema focusing on structure.

  If you are willing to serve on one or more of the above-identified NIH Study Sections, please contact LE&RN at LERN@LymphaticNetwork.org with the following information:

  * Name
  * Affiliation
  * Study Section(s) on which you are willing to serve
  * In 50 words or less, your qualifications for each Study Section selected
  * Include CV

  Investigators will not be able to review their own research or research on which they are collaborators. However, this will not prevent your research from being reviewed by the Study Section. Per NIH: If a researcher is on a Study Section and has an application, his or her application is reviewed by a special emphasis panel. This is a common practice that happens all the time. This should not be an obstacle to joining a Study Section.

• Online Partnership to Accelerate Research

  OnPAR (Online Partnership to Accelerate Research) is a matchmaking platform where applicants and non-government funders come together.  Leidos Health’s Life Sciences has partnered with NIH and other funding organizations to accelerate the biomedical research and development enterprise by matching high-scoring unfunded applications with private biomedical foundations and/or industries seeking to fund promising research via OnPAR (e.g., for NIH these would be applications within the 30th percentile but are beyond the funding cutoff).

  OnPAR has member organizations and matches the unfunded applications with the funding organization.  For more information, please visit https://onpar.leidosweb.com/.

  Learn More >